Member Info for crumbs

What everyone is getting a custard cream!!?

The HAGE results will now advance to PD1 combo tests

Van Geest...Steph is a big fan of LD's approach... a lot of work is going on
Really what I think LD and her work is too valuable for the vehicle that is AIM listed scancell.... Why we are not under the umbrella of a Genetech already I really really do not know... know they are on the scene though and that is best I can say about it... so much effing possibly world changing tech!... now new platform too!

GMB too.... so that is potential ImmunoBody use in prostate, TNBC and GMB.... oh for the funding... not heard of WT-1-ImmunoBody before?

'Dr. Stéphanie McArdle leads the development and assessment of peptide-derived tumour associated antigen vaccines, including a novel and patented prostatic acid phosphatase-derived vaccine (PAP), and a HAGE and NY-ESO1 based vaccines. In addition, two other vaccines are currently being assessed in collaboration with Scancell Ltd (SCIB1 and WT-1-Immunobody®) for the treatment of GBM.'

Might be of interest this... but ImmunoBody as a platform is not being neglected....

https://www.ejcancer.com/article/S0959-8049(18)30058-3/abstract
A novel PAP derived vaccine for the treatment of advanced prostate cancer

HAGE derived peptide as a vaccine to prevent relapse in TNBC patients

All using ImmunoBody

Stability at this stage is most important... probably some Latin phrase for it

Indeed also from that file:

SCIB1 US IND and Phase 2 study
The Company's Investigational New Drug (IND) application for SCIB1 is expected to be filed with the Food
and Drug Administration (FDA) during the first half of 2018. Following the pre-IND meeting in 2017, the FDA
suggested that technical data from Ichor’s new TriGrid 2.0 clinical device should be submitted 30-60 days prior
to Scancell’s own FDA submission. Ichor has now submitted the required data to the FDA, and therefore,
subject to funding, patient enrolment into this trial is now expected to commence in the second half of 2018.
The study, which will be a Phase 2 checkpoint inhibitor combination study with SCIB1 in patients with advanced
melanoma, will be led by Principal Investigator Dr Keith Flaherty, Director of the Termeer Center for Targeted
Therapy at Massachusetts General Hospital and Associate Professor at Harvard Medical School.

From Feb 2018:

Dr Keith Flaherty commented: “Although the checkpoint inhibitors have improved the prognosis for many
melanoma patients, a significant proportion of patients do not respond to these new regimes. The combination
of SCIB1 with a checkpoint inhibitor may significantly expand the population of patients who benefit from
immunotherapy.”
Dr Cliff Holloway, CEO of Scancell, said: “We are delighted to see the data from our Phase 1/2 study published
in the respected peer-reviewed journal OncoImmunology. The continuing survival of these patients is
impressive as many had undergone multiple resections of their tumours prior to SCIB1 treatment but have had
no evidence of any further disease recurrence. This compares extremely favourably with checkpoint inhibitors,
but has the advantage of being associated with significantly less toxicity. We remain on track to submit an
IND to enable our Phase 2 study combining SCIB1 with a checkpoint inhibitor to start in the second half of this
year.”

https://www.scancell.co.uk/file-manager/PDFs/peer-reviewed-publicaton-scib1-final.pdf

The vaccine is manufactured already...plus that trial ought to be very successful,too late to not do it now surely

TF interesting angle.. thing is the US adventure as of yet is not over... certainly he never brought us any US investment though!... we have some 3 year plan in place where data is very much the focus but no trials no data... and our other 2 pivotal trials are UK based and may well begin before the US one we have been waiting on since JC arrived... so yeah maybe you are right.. an expensive we cannot afford ?... I don't know but he seems keen to be involved and has put one hand in his pocket to buy shares despite having the other in raised funds pot :)

Well on the recent news yes the UK arm now does look like scancell became aware the US trial was not happening as smoothly as hoped and put in that new arm as insurance... we have the vaccine manufactured now at great expense and the Ichor licensing in place... not to mention the scientific rationing behind it makes it compelling as... well the chances very much favour the results will be excellent... got to have that trial...

Yes. the SCIB1 combo elephant is back in the room... hopefully good news will come before the FDA are happy and green light the trial... Grand Challenge .. BioNtech... and the left field news that has already seemingly left the field lol

But but... the trial is still very much expected to happen?FDA hold up being just a non-fatal blip surely too much has been invested in it to abandon now and indeed the PR from having the best of the best in the biggest market and the exposure we would get on success is still very much worth it.... hopefully BOD will put the picture straight and explain the UK angle to that trial that suddenly appeared ...SCIB1 still our most advanced and valuable asset... for now

Isn't the San Diego office just a table in Chippers kitchen anyways?

Beware the Ides of March!

Deal does look to be the one we will actually do... and it will be good for many reasons but number one is it will not dilute scancells moditope ip at all... the deal will not wait for modi1 trial data as modi1 is being used in a completely different way it will to my understanding basically educate extracted t cells to hunt targeted cancer and only targeted cancer hopefully very efficiently and with none of the nasty side effects others in that field are experience as their t cells seem to attack not just cancer but self... thats the beauty if it works moditope couldl be the key to 'safe' TCR therapies

yeah was CH who is coming out with that new plan... the fact is though it is BS we see massive preclinical deals all the time plus Genetech are well known for wanting in on new techs pre-trial that is their prefered way as they like to be involved at the earliest stage of science they like.... I get that if a product proves itself in a trial it becomes so much more valuable and if you keep the ip tight through the process great... but SCIB1 already proved itself and no deal... reasons could be many and I think are mostly to do with - fashion it is not a CI it is not an adoptive t cell therapy like a Car T and those are the immunotherapies that are in fashion and pharmas and markets are happy to throw $billions at...it's a vaccine and vaccines went right out of fashion with GSKs massive costly failure and other failures... but hey scancell found a way to make vaccines work!... noticed no mention of in talks with pharmas on last report unlike the previous ones... could be that is because we are not getting anywhere satisfactory with them and will go as far as we can ourselves in proving techs or something is coming... as of yet it looks more like the former.

True but Scib2 is covered by CRUK we just need to know how arrangements for that are progressing and what delivery method is to be used.... Meanwhile let's get modi1 in tral ASAP it seems to only platform we ha e a chance of a deal on... Also they need to introduce new platform properly

SCIB1 combo ought to still be happening too!

Too early to say if they screwed up on it as we do not know the issue the FDA have it could well be both scancell and Ichor gave the FDA all they asked for only for them then to come back and ask for more details on certain aspects... like I have said before Inovio had this experience too in applying for a trial using their latest device the FDA asked for more info but we have not been given that info here yet..... so could be they messed it up or they did not and it is just the FDA being the FDA hopefully the BOD will be open about it all .... inovio had their issues in Oct 2016 all resolved by June 2017... so this could be the same here... meaning the trial will not start till next summer